Ashish M. Kamat, MD, MBBS(@UroDocAsh) 's Twitter Profile Photo

FDA Grants priority review to Enfortumab Vedotin for based on EV-201 trial data from showing 44% ORR; 12% CR and 32% PR
Congrats Dan Petrylak Arjun Balar MD Matt Galsky & colleagues shar.es/aXwOze

account_circle
OncologyGo(@OncologyGo) 's Twitter Profile Photo

Don't miss OncologyGo's Oncology World Cup, filmed exclusively at ! Watch the full video now, exclusively on the app—download it today!

account_circle
Shearwood McClelland III, M.D.(@TheDrWood) 's Twitter Profile Photo

A great aspect of attending the first in-person ASCO meeting since is the on-site fellowship with colleagues. Here I am with Forrest Kwong (@OHSUSOM class of 2023 and future ) following his excellent poster presentation! ASCO ASTRO The McClelland Lab

A great aspect of attending the first in-person @ASCO meeting since #ASCO19 is the on-site fellowship with colleagues. Here I am with Forrest Kwong (@OHSUSOM class of 2023 and future #RadOnc) following his excellent #ASCO22 poster presentation! @ASCO @ASTRO_org @DrMcClellandLab
account_circle
ProstateUK Profs(@ProstateUKProfs) 's Twitter Profile Photo

This year’s wrapped up last week, after a packed schedule of prostate cancer breakthroughs. Our Deputy Director of Research, Dr Matt Hobbs, was there – check out his blog to find out what the standout discoveries were for him (1/2)

🔊 bit.ly/2F4UyHv

account_circle
Filip Janku(@FilipJankuMD) 's Twitter Profile Photo

I am glad to see this being published 4 years after being presented at . I still think the efficacy of FF-10502 in gem heavily pretreated was of interest.

I am glad to see this being published 4 years after being presented at #ASCO19. I still think the efficacy of FF-10502 in gem heavily pretreated #cholangiocarcinoma was of interest.
account_circle